JHS Expands Sterile Manufacturing at Recently Warned Plant

By Dan Stanton

- Last updated on GMT

JHS Expands Sterile Manufacturing at Recently Warned Plant

Related tags: Life

Jubilant HollisterStier (JHS) says expansion of its sterile manufacturing capacity at its facility in Kirkland, Canada will be used to fulfill several new contracts.

The contract manufacturing organization (CMO) is increasing its ampoule production capacity at the plant by nearly 200 percent as part of a first phase expansion of its sterile manufacturing services offering.

In a statement the company said a significant part of the expansion would be dedicated for new customer products and JHS’ CEO, Marcelo Morales, added: “We have been fortunate to secure several new contracts that will utilize our expanded capacity starting this year.”

The company is adding a new ampoule filling line utilizing a rigid barrier system which is scheduled to be operational early next month.

GMP Violations

In February this year the Kirkland plant was hit by a warning letter​ from the US Food and Drug Administration (FDA) who cited a number of violations, including failure to confirm to final specifications for the drug product, and failure to establish criteria for sampling and testing.

This came as a result of an inspection in 2012 that noted “water running on the floor of the equipment wash room that was tracked into the dirty equipment staging room and further, into the pharmaceutical corridor leading to the sterile production hallway, the line, and the vial filling area.”

Outsourcing-Pharma.com contacted both JHS and its parent body, India-headquartered Jubilant Life Sciences, by phone and email but comments regarding both the new expansion and the facility’s approach to quality were not available at the time of going to press.

However, a statement from Jubilant Life Science in February said manufacturing at the Kirkland had not been affected by the warning letter and added “JHS is committed to implementing the necessary corrective actions required to address the FDA concerns, and will work closely with the FDA to bring resolution to this matter.”

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars